DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
CB-839 is an investigational drug.
There have been 18 clinical trials for CB-839. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.
The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are nine US patents protecting this investigational drug and ninety international patents.
Recent Clinical Trials for CB-839
|CB-839 in Combination With Niraparib in Platinum Resistant Breast Cancer (BRCA) -Wild-type Ovarian Cancer Patients||University of Alabama at Birmingham||Phase 1|
|CB-839 HCl in Treating Patients With Specific Genetic Mutations and Metastatic or Unresectable Solid Tumors or Malignant Peripheral Nerve Sheath Tumors||National Cancer Institute (NCI)||Phase 2|
|A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors||Calithera Biosciences, Inc||Phase 1/Phase 2|
Top disease conditions for CB-839
Top clinical trial sponsors for CB-839
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CB-839||Start Trial||Combination therapy with glutaminase inhibitors||Calithera Biosciences, Inc. (South San Francisco, CA)||Start Trial|
|CB-839||Start Trial||Compositions and methods of treating cancer harboring PIKC3A mutations||Case Western Reserve University (Cleveland, OH)||Start Trial|
|CB-839||Start Trial||Combination therapy with glutaminase inhibitors and immuno-oncology agents||Calithera Biosciences, Inc. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CB-839||European Patent Office||3503893||2036-08-25||Start Trial|
|CB-839||World Intellectual Property Organization (WIPO)||2018039441||2036-08-25||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|